Zhang Jing, Goodlett David R, Montine Thomas J
Department of Pathology, University of Washington, Seattle, Washington 98104, USA.
J Alzheimers Dis. 2005 Mar;8(4):377-86. doi: 10.3233/jad-2005-8407.
The clinical diagnosis of major neurodegenerative disorders, e.g. Alzheimer's disease, Parkinson's disease, and dementia with Lewy body, remains unsatisfactory based on current clinical criteria and limited laboratory investigations. The possibility of identifying multiple novel biomarkers for neurodegenerative diseases, those related to disease pathogeneses in particular, has been greatly enhanced with recent advances in genomics, proteomics, and metabolomics. In this chapter, we will be reviewing a few issues related to proteomic identification of proteins in human cerebrospinal fluid (CSF) as well as unique protein markers that could be used for clinical diagnosis of various neurodegenerative diseases or monitoring their progression. Great attention has been directed to practical considerations and limitations of several major aspects of proteomic analysis of human CSF.
基于目前的临床标准和有限的实验室检查，诸如阿尔茨海默病、帕金森病和路易体痴呆等主要神经退行性疾病的临床诊断仍不尽人意。随着基因组学、蛋白质组学和代谢组学的最新进展，识别多种神经退行性疾病新型生物标志物（尤其是那些与疾病发病机制相关的生物标志物）的可能性已大大提高。在本章中，我们将回顾与人类脑脊液（CSF）中蛋白质的蛋白质组学鉴定相关的一些问题，以及可用于各种神经退行性疾病临床诊断或监测其进展的独特蛋白质标志物。人们已高度关注人类脑脊液蛋白质组学分析几个主要方面的实际考量和局限性。
